Pharmaceuticals
News Category
NanoViricides Secures $3.8 Million in Registered Direct Offering to Advance Antiviral Drug Development
NanoViricides announced a $3.8 million registered direct offering with a fundamental institutional investor to fund its broad-spectrum antiviral drug ...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance Cancer Therapies
VERAXA Biotech appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor cancer therapies, leveraging his two decades ...
VERAXA Biotech Receives Positive Regulatory Feedback from German PEI for BiTAC(R)-TCE Program
VERAXA Biotech AG obtained Scientific Advice from Germany's Paul-Ehrlich-Institute, supporting its development strategy for the lead BiTAC(R)-TCE cand...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on development st...
Siegfried Appoints Eduardo Montanha as Chief Operating Officer to Drive Integrated Operations Strategy
Siegfried has appointed Eduardo Montanha as COO to lead its integrated global operations, supporting the company's strategy of offering end-to-end sol...
NextPlat Corp Expands PharmcoRx With Planned Florida Pharmacy Acquisition
NextPlat Corp's agreement to acquire a Florida pharmacy for $1.5 million expands its PharmcoRx retail footprint into an underserved rural market, supp...
Onco-Innovations Completes Analytical Reference Standard Program for ONC010, Advancing Toward Clinical Readiness
Onco-Innovations Limited has completed an analytical reference standard program for its lead oncology candidate ONC010, strengthening its CMC framewor...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC T-Cell Engager Program
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager, partnering with ATUM to advance toward IND/CTA-enabling studies, mar...
Sustained Release Polymers Market Set to Reach USD 7.8 Billion by 2036 as Drug Delivery Innovation Reshapes Pharmaceutical Formulation Strategies
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, driven by rising chronic diseases,...
VERAXA Biotech Advances BiTAC Pipeline and Seeks Pharma Partnerships
VERAXA Biotech AG reported progress in its BiTAC platform and partnering strategy, with four BiTAC-based T-cell engager programs targeting solid tumor...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program, aiming to improve tumor selectivity and reduce off-tumor tox...
VERAXA Biotech AG Shareholders Should Note Strong Deal Activity in Antibody Therapeutics Sector
The antibody therapeutics sector, particularly antibody-drug conjugates and T-cell engagers, continues to see strong deal activity, highlighting the p...
Ace Therapeutics Launches Comprehensive Preclinical Pain Research Platform
Ace Therapeutics announces a full-spectrum preclinical analgesic drug development platform with over 20 validated pain models, aiming to accelerate pa...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing across its German network to counter sustained margin...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Depression Trial Enrollment Nears Completion
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003 in major depressive disorder, with topline data expe...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated dr...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics Inc. has repaid all outstanding amounts under its revolving credit facility, demonstrating strong cash flow and financial stabilit...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating three U.S. sites for a vertically integrated contrast media manufacturing facility, aiming to reduce costs and ...
Earth Science Tech Inc. (ETST) Transforms into Diversified Holding Company with Telemedicine and Pharmacy Ecosystem
Earth Science Tech Inc. has completed a vertically integrated telehealth and pharmacy ecosystem, positioning itself at the intersection of telemedicin...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals announces submission of a five-year exploration permit for its Frances Creek barite project, including a 2,000-tonne test ext...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Barium and Iodine Product Development
Voyageur Pharmaceuticals closed a non-brokered private placement raising $5 million to fund FDA licensing for its barium contrast products and develop...
Kairos Pharma Updates on Pipeline Expansion and Clinical Milestones in Mid-Year 2026 Shareholder Update
Kairos Pharma announced plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, and provided updates on its clinical...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Potential in BioMedWire Podcast
Quantum BioPharma Ltd. discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial product unbuzzd for alcohol metabolism, em...
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma's clinical-stage multiple sclerosis program targeting demyelination and its diversified portfolio spanning therapeutics and consumer...
Redwood AI Corp. Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announces DTC eligibility for its common shares to simplify U.S. trading and enhance liquidity, and hires IBN for a $114,000 investor...
Carmed Pharmaceuticals Expands U.S. Presence with CityBiz Feature and Multi-Channel Distribution
Carmed Pharmaceuticals, a Turkey-based company specializing in carvacrol-based formulations, expands into the U.S. market through a CityBiz executive ...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Drug Discovery
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-success protein synthesis in 3 hours, integrating with AI-driven high-throughput screeni...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox and Expands Orphan Drug Strategy
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides announced a $2 million registered direct offering with a single institutional investor, selling common shares and warrants to fund its c...
Lantern Pharma Closes $4.4 Million Registered Direct Offering to Advance AI-Driven Precision Oncology Pipeline
Lantern Pharma raised $4.4 million in a registered direct offering, providing capital to advance its AI-powered precision oncology pipeline and potent...
Tonix Pharmaceuticals to Present at Two Major Investor Conferences in May
Tonix Pharmaceuticals will participate in the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual Virtual Healthcare Conference, high...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for...
LIXTE Biotechnology's LB-100 Positions as Novel Enhancer of Cancer Therapies
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to enhance chemotherapy and immunotherapy effectiveness in solid tumors with high ...
Soligenix Showcased for Efficient Platform-Based Drug Development Strategy
Soligenix leverages synthetic hypericin across multiple dermatologic indications, demonstrating how platform technology can streamline drug developmen...
PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual General Meeting
At its fifth annual general meeting, PolyPeptide Group AG secured shareholder approval for all board proposals, including re-election of directors and...
LIXTE Biotechnology Files 2025 Annual Report, Highlights Clinical Advances and Strategic Growth
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing leadership changes, progress with lead compound LB-100, expanded clini...
LIXTE Biotechnology Holds World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
LIXTE Biotechnology's LB-100 is the only clinical-stage PP2A inhibitor with potential to enhance cancer therapy by sensitizing tumors to treatment and...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its board, aiming to leverage his expertise in performance culture and organizational tran...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects with Feasibility Studies and FDA Pathway
Voyageur Pharmaceuticals provides a corporate update on its vertically integrated barium and iodine contrast media projects, including completion of b...
Soligenix Receives Positive EMA Opinion for Orphan Drug Designation of Dusquetide in Behcet's Disease
Soligenix announced a positive opinion from the EMA's Committee for Orphan Medicinal Products for dusquetide in Behcet's disease, potentially unlockin...
NETHERTON NOW Campaign Marks Rare Disease Day with 2 Million Video Views, Highlighting Unmet Needs in Netherton Syndrome
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has generated 2 million video views and 24 million impressions, underscoring the growing globa...
Oncotelic Therapeutics Featured in BioMedWire Editorial Highlighting Late-Stage Biotech M&A Trends
Oncotelic Therapeutics' late-stage oncology and CNS programs align with growing M&A focus on de-risked, clinically validated assets, as highlighted by...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced publication of Phase 2a trial results in Nature Medicine showing that a single dose of SPL026 significantly reduced depressive ...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys announced positive Phase 2 results for its immunotherapy MVP-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladde...
Quantumzyme Corp. Unveils 2025 Progress and Strategic Blueprint for 2026, Including AI Expansion and Name Change
Quantumzyme Corp. provided a 2025 corporate update highlighting research advancements and AI integration, and outlined 2026 priorities including a pro...
Creative Biolabs Upgrades Biosimilar Development Platform with Enhanced Physicochemical and Biological Characterization
Creative Biolabs announces a strategic upgrade to its biosimilar development and CDMO platform, enhancing physicochemical characterization and biologi...
Protheragen Offers Comprehensive Drug Analysis Solutions Integrating Stability, Impurity, and Chemical-Physical Testing
Protheragen's integrated drug analysis services, including stability studies, impurity testing, and chemical-physical testing, support pharmaceutical ...
Lixte Biotechnology to Present at DealFlow Discovery Conference, Highlighting LB-100 Progress
Lixte Biotechnology Holdings announced its participation in the DealFlow Discovery Conference, where CEO Geordan Pursglove will meet with investors to...